Overview of completed/ongoing phase 3 clinical trials involving apixaban
| . | Comparator . | No. of patients (approximate) . | Results expected/published . | Acronym . |
|---|---|---|---|---|
| AF | VKA | 15 000 | 2011 | ARISTOTLE |
| VTE, primary prophylaxis | ||||
| Orthopedic | LMWH | 6 200 | 2009,7 2010 | ADVANCE-1,2 |
| Orthopedic | LMWH | 5 400 | 2010 | ADVANCE-3 |
| Medical | LMWH | 6 500 | Early 2010 | ADOPT |
| VTE acute treatment | LMWH + VKA | 2 900 | 2012 | AMPLIFY |
| VTE secondary prevention | Placebo (before randomization, all patients have received 6-12 months of anticoagulation) | 2 400 | 2012 | AMPLIFY extension study |
| Post–acute coronary syndrome | Placebo (all patients will receive standard treatment, such as aspirin, β-blocker) | 11 000 | 2012 | APPRAISE-2 |
| . | Comparator . | No. of patients (approximate) . | Results expected/published . | Acronym . |
|---|---|---|---|---|
| AF | VKA | 15 000 | 2011 | ARISTOTLE |
| VTE, primary prophylaxis | ||||
| Orthopedic | LMWH | 6 200 | 2009,7 2010 | ADVANCE-1,2 |
| Orthopedic | LMWH | 5 400 | 2010 | ADVANCE-3 |
| Medical | LMWH | 6 500 | Early 2010 | ADOPT |
| VTE acute treatment | LMWH + VKA | 2 900 | 2012 | AMPLIFY |
| VTE secondary prevention | Placebo (before randomization, all patients have received 6-12 months of anticoagulation) | 2 400 | 2012 | AMPLIFY extension study |
| Post–acute coronary syndrome | Placebo (all patients will receive standard treatment, such as aspirin, β-blocker) | 11 000 | 2012 | APPRAISE-2 |